Get the Stockscreener App
20.10
2.38%
-0.49
After Hours:
20.16
0.06
+0.30%
Vor Biopharma Inc stock is traded at $20.10, with a volume of 1.59M.
It is down -2.38% in the last 24 hours and up +52.74% over the past month.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
See More
Previous Close:
$20.59
Open:
$20.48
24h Volume:
1.59M
Relative Volume:
1.35
Market Cap:
$1.09B
Revenue:
-
Net Income/Loss:
$-883.08M
P/E Ratio:
-0.0603
EPS:
-333.4782
Net Cash Flow:
$-150.65M
1W Performance:
+8.06%
1M Performance:
+52.74%
6M Performance:
+72.24%
1Y Performance:
-47.38%
1-Day Range:
$19.21
$21.00
1-Week Range:
$17.98
$22.22
52-Week Range:
$6.50
$65.80
Vor Biopharma Inc Stock (VOR) Company Profile
Name
Vor Biopharma Inc
Sector
Industry
Phone
617-655-6580
Address
500 BOYLSTON STREET, BOSTON
Compare VOR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
20.10 | 997.56M | 0 | -883.08M | -150.65M | -333.48 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-26 | Initiated | Jefferies | Buy |
| Mar-19-26 | Initiated | Wells Fargo | Overweight |
| Jan-09-26 | Initiated | Citigroup | Buy |
| Dec-17-25 | Initiated | TD Cowen | Buy |
| Dec-09-25 | Initiated | JP Morgan | Overweight |
| Nov-25-25 | Resumed | Wedbush | Neutral |
| Oct-15-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-24-25 | Upgrade | Stifel | Hold → Buy |
| Jun-30-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-26-22 | Initiated | Wedbush | Outperform |
| Apr-27-22 | Initiated | Goldman | Neutral |
| Dec-17-21 | Initiated | H.C. Wainwright | Buy |
| Dec-03-21 | Initiated | Robert W. Baird | Outperform |
| Dec-02-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Mar-25-21 | Initiated | B. Riley Securities | Buy |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Mar-03-21 | Initiated | Evercore ISI | Outperform |
| Mar-02-21 | Initiated | Goldman | Sell |
| Mar-02-21 | Initiated | Stifel | Buy |
View All
Vor Biopharma Inc Stock (VOR) Latest News
Why Vor Biopharma (VOR) Is Up 24.5% After Broad FTSE Russell Index Inclusion And What's Next - Yahoo Finance
Vor Biopharma Inc.(NasdaqGS: VOR) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Vor Biopharma Inc.(NasdaqGS: VOR) added to Russell 2500 Growth Benchmark - marketscreener.com
Vor Biopharma Inc.(NasdaqGS: VOR) added to Russell 2000 Index - marketscreener.com
Vor Biopharma Inc.(NasdaqGS: VOR) added to Russell 2000 Value Benchmark - marketscreener.com
Vor Biopharma Inc.(NasdaqGS: VOR) added to Russell Microcap Value Benchmark Index - marketscreener.com
Vor Biopharma Inc.(NasdaqGS: VOR) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Vor Biopharma Inc.(NasdaqGS: VOR) added to Russell 2000 Growth Benchmark - marketscreener.com
Vor Biopharma Inc.(NasdaqGS: VOR) added to Russell 3000E Growth Benchmark - marketscreener.com
Vor Biopharma Inc.(NasdaqGS: VOR) added to Russell Microcap Index - marketscreener.com
Enterprise value to EBITDA forward of Vor Biopharma Inc. – NASDAQ:VOR - TradingView
Enterprise value to EBIT forward of Vor Biopharma Inc. – NASDAQ:VOR - TradingView
Vor Biopharma, Inc. Actuals & Estimates (NASDAQ:VOR) - TradingView
Vor Biopharma (VOR) Surges 8% as Shares Test Key Resistance at $16.95Imbalance Zone - dars.gov.et
Vor Biopharma | 4: Statement of changes in beneficial ownership of securities-Director RA CAPITAL MANAGEMENT, L.P.moomoo - Moomoo
VOR Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Vor Biopharma Inc. – NASDAQ:VOR - TradingView
Vor Biopharma Inc (VOR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vor Biopharma Inc (VOR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Vor Biopharma Inc (VOR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
VOR Stock Price, Quote & Chart - ChartMill
Vor Biopharma Inc (VOR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Vor Biopharma Inc (VOR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Vor Biopharma Inc (VOR) Institutional Confidence - TradingKey
Vor Biopharma Inc (VOR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Vor Biopharma Inc (VOR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Vor Biopharma Inc (VOR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Vor Biopharma Q1 2026 Earnings: Deep EPS Miss Amid Ongoing R&D Investment; Stock Edges HigherOne-Time Loss Impact - newsline.com
Vor Biopharma (VOR) Stock Analysis Report | Financials & Insights - Benzinga
[Form 4] Vor Biopharma Inc. Insider Trading Activity - Stock Titan
Vor Biopharma (VOR) director receives 53,283 stock options at $14.09 strike - Stock Titan
Vor Biopharma (VOR) grants Alexander Cumbo 56,345 stock options - Stock Titan
Vor Biopharma (NASDAQ: VOR) updates and wins approval for 2021 equity plan - Stock Titan
Vor Biopharma (VOR) Stages 3.12% Rally: Potential Breakout Above $15.26 in Sight?Jelly Roll Trade - newsline.com
Vor Biopharma (VOR) director receives 57,162 stock options for RA Capital fund - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Vor Bio gains boost from telitacicept IgA nephropathy approval - TipRanks
Vor Bio (VOR) drug telitacicept gains China NMPA nods in IgAN and Sjögren’s - Stock Titan
Vor Bio (VOR) Secures Conditional Approval for Telitacicept in C - GuruFocus
Vor Biopharma Inc. and RemeGen Co., Ltd. Receives NMPA Conditional Approval For Telitacicept For The Treatment Of IgA Nephropathy In China - marketscreener.com
Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China - Yahoo Finance
Vor Biopharma (VOR) Slips Over 8% as Biotech Sentiment WeighsThematic ETF Flow - newsline.com
Vor Biopharma (VOR) Declines Over 8% as Biotech Sector Faces Headwinds; Key Support Levels TestedMomentum Factor - newsline.com
Vor Biopharma (VOR) Drops Over 8% as Shares Approach Key SupportMax Pain Level - newsline.com
GREAT POINT PARTNERS LLC's Vor Biopharma Inc(VOR) Holding History - GuruFocus
VOR Stock Chart | VOR BIOPHARMA INC (NASDAQ:VOR) - ChartMill
Vor Biopharma’s Phase 3 Sjögren’s Trial Puts Telitacicept on Investors’ Radar - TipRanks
VOR: Advancing telitacicept in global phase III trials for MG and Sjögren's, targeting major markets - TradingView
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Biotech Vor Bio hands 61,050 options, 12,900 RSUs to new staff - Stock Titan
VOR Q1 2026 Earnings: Staggering EPS Miss with Negative Revenue and Sharp Stock DeclineCEO Earnings Statement - newsline.com
Vor Biopharma Inc Stock (VOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vor Biopharma Inc Stock (VOR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 17 '26 |
Sale |
16.28 |
458,411 |
7,462,931 |
2,739,208 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 20 '26 |
Sale |
15.77 |
171,963 |
2,711,857 |
2,567,245 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 13 '26 |
Sale |
16.15 |
530,610 |
8,569,352 |
3,404,998 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 14 '26 |
Sale |
15.97 |
153,735 |
2,455,148 |
3,251,263 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 15 '26 |
Sale |
16.01 |
53,644 |
858,840 |
3,197,619 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 08 '26 |
Sale |
16.48 |
484,104 |
7,977,786 |
4,071,637 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 09 '26 |
Sale |
16.59 |
135,201 |
2,242,985 |
3,936,436 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 10 '26 |
Sale |
15.75 |
828 |
13,041 |
3,935,608 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 06 '26 |
Sale |
16.59 |
589,257 |
9,777,898 |
4,555,741 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 02 '26 |
Sale |
18.23 |
260,000 |
4,741,066 |
5,144,998 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):